Antibody Humanization

Humanization with Precision

We humanize antibodies for the development of safer drugs – combining sequence analysis, structural insights, and experimental validation.

Let‘s humanize your antibody
yumab-antibody-humanization-icon
  • Preserving Binding Properties
  • Experimental Validation
  • Optimized for Developability

Delivering Humanized Antibodies for Safer Drugs

YUMAB® discovery platform generates fully human antibodies closest to natural germline among those on the market. For non-human antibodies, YUMAB provides optimized bioinformatic humanization solutions to generate humanized antibody variants mimicking sequence characteristics close to fully human antibodies.

All antibody variants are engineered to preserve the original binding affinity and specificity of the non-human antibodies while ensuring low immunogenicity and high sequence stability, making them ideally suited for clinical development. Combined with advanced in silico liability analysis and engineering tools, YUMAB delivers optimized candidates that meet the highest standards of efficacy, safety, and manufacturability.

YUMAB’s Humanization Approach for Therapeutic Antibody Development

At YUMAB, we have established a streamlined five-step workflow that transforms non-human antibodies into humanized clinical candidates. Our process integrates advanced bioinformatics, rational human framework selection, CDR grafting, and structure-guided engineering to maintain affinity, stability, and developability. Comprehensive functional and biophysical testing ensures that each variant meets the highest standards for safety, efficacy, and manufacturability. The result is a robust, humanized lead candidate optimized for successful preclinical and clinical development.

AI-assisted identification of the optimal human acceptor framework for optimal structure homology

arrow-yellow-right-thin1

Grafting of non-human CDR onto human acceptor framework

arrow-yellow-left-thin1

Structure guided backmutation of crucial amino acid residues essential for folding and function

arrow-yellow-right-thin1

Generation and production of several VH and VL variant combinations to identify the humanized antibody with optimal function, stability, and expression

arrow-yellow-left-thin1

Expression and characterization of the humanized antibody

Let us turn your animal derived lead into a human therapeutic

Questions and Answers

Antibody humanization is the process of modifying a non-human antibody sequence to make it more human-like while preserving its desired binding and functional properties. It is commonly used to reduce the potential immunogenicity of therapeutic antibodies.
Humanization is typically performed when a promising antibody originates from a non-human source and is intended for therapeutic development. The timing depends on the antibody and development strategy and can be performed as part of lead optimization.
Humanization replaces selected non-human framework residues with human sequences while preserving the antibody’s antigen-binding regions and structure. The aim is to reduce potential immunogenicity while maintaining affinity, specificity, stability, and biological activity. YUMAB experimentally evaluates different designs to identify humanized variants that retain the parental antibody’s performance.
The strategy is tailored to the individual antibody. We consider the antibody sequence, structural characteristics, CDRs, framework regions, and desired developability profile to design and evaluate suitable humanized variants.
All humanized variants are tested in the wet lab.
Yes. YUMAB can humanize existing antibody leads, including antibodies generated by other discovery platforms or organizations. The starting sequence and available characterization data are evaluated to develop an appropriate humanization strategy.
A typical project can be completed within three months, including design, generation, and experimental characterization of humanized variants.

Talk to a Scientist

Dr. Phillipp Kuhn
VP Services & Operations

Discuss Your Project

We typically reply within 1-2 business days.